Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 9,024 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 9,024 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $68.62, for a total value of $619,226.88. Following the sale, the director owned 44,637 shares in the company, valued at approximately $3,062,990.94. This trade represents a 16.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Raman Singh also recently made the following trade(s):

• On Monday, September 14th, Raman Singh sold 8,468 shares of Liquidia stock. The shares were sold at an average price of $66.16, for a total value of $560,242.88.

Liquidia Stock Performance

Shares of LQDA opened at $65.72 on Wednesday. The stock has a 50-day simple moving average of $76.88 and a 200-day simple moving average of $59.93. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The stock has a market capitalization of $5.88 billion, a PE ratio of 47.97 and a beta of 0.53. Liquidia Corporation has a 1 year low of $21.15 and a 1 year high of $93.61.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the company posted ($0.49) earnings per share. The firm’s quarterly revenue was up 1842.1% on a year-over-year basis. On average, analysts predict that Liquidia Corporation will post 2.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LQDA has been the topic of a number of analyst reports. BTIG Research raised their price objective on shares of Liquidia from $109.00 to $111.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Raymond James Financial reiterated a “strong-buy” rating and set a $106.00 target price on shares of Liquidia in a research note on Thursday, August 13th. Stephens set a $130.00 target price on Liquidia in a report on Friday, July 24th. Needham & Company LLC raised their price target on Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Royal Bank Of Canada set a $130.00 price target on Liquidia in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $98.08.

Hedge Funds Weigh In On Liquidia

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its holdings in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Liquidia during the 2nd quarter worth approximately $29,694,000. Eversept Partners LP grew its stake in Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after buying an additional 167,949 shares during the last quarter. Seven Fleet Capital Management LP increased its position in Liquidia by 25.2% during the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after buying an additional 51,727 shares during the period. Finally, Pale Fire Capital SE increased its position in Liquidia by 2.4% during the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock worth $14,657,000 after buying an additional 8,985 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.